Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQF6422 in Healthy Overweight or Obese Subjects
NCT07794111Phase 1Not yet recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQF6422 in obesity (5 arms), sponsored by Chia Tai Tianqing. Primary endpoint: Adverse event rate at Day 112. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
TQF6422
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07794111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794111.